Indivior (LON:INDV) Price Target Cut to GBX 1,500 by Analysts at Deutsche Bank Aktiengesellschaft

Indivior (LON:INDV) had its price target trimmed by Deutsche Bank Aktiengesellschaft from GBX 2,350 ($30.10) to GBX 1,500 ($19.21) in a report released on Tuesday, Digital Look reports. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

Indivior Trading Up 3.8 %

INDV traded up GBX 28.50 ($0.37) during trading on Tuesday, reaching GBX 785 ($10.06). 27,709,025 shares of the company’s stock were exchanged, compared to its average volume of 721,224. The company has a current ratio of 0.93, a quick ratio of 1.52 and a debt-to-equity ratio of 2,790.00. Indivior has a one year low of GBX 653 ($8.36) and a one year high of GBX 1,938 ($24.82). The firm has a fifty day moving average price of GBX 1,323.63 and a two-hundred day moving average price of GBX 1,420.38. The stock has a market capitalization of £1.06 billion, a PE ratio of 26,233.33, a price-to-earnings-growth ratio of -5.57 and a beta of 0.06.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.